Literature DB >> 27313754

Association of STAT3 with Cx26 and Cx43 in human uterine endometrioid adenocarcinoma.

Urszula Sulkowska1, Andrzej Wincewicz Febp2, Stanislaw Sulkowski1.   

Abstract

Signal transducer and activator of transcription-3 (STAT3) drives endometrial carcinogenesis, while signaling via gap junctions gets weakened during cancer progression. Connexin 26 (Cx26), Cx43 and STAT3 were immunohistochemically evaluated in 78 endometrioid adenocarcinomas: Nuclear expression of STAT3 positively correlated with cytoplasmic immunoreactivity to Cx43 (P=0.004, r=0.318) and Cx26 (P=0.006, r=0.309). STAT3 correlated with Cx43 (P=0.022, r=0.411) and Cx26 (P=0.008 r=0.466) in G1 tumors. A statistically significant linkage remained in G2 cancers between STAT3 and Cx43 (P=0.061, r=0.262) and Cx26 (P=0.016, r=0.331); however, no correlations were observed in G3 tumors. STAT3 was significantly associated with Cx 43 (p=0.003, r=0.684) and Cx26 (p=0.049, r=0.500) in estrogen receptor (ER) negative adenocarcinomas. STAT3 did not correlate with Cx43 in ER positive adenocarcinomas; however, STAT3 expression remained correlated with Cx26 expression (P=0.035, r=0.268). In progesterone receptor negative tumors STAT3 was significantly associated with Cx43 (P=0.035, r=0.451) and Cx26 (P<0.0001, r=0.707). However, in PgR positive adenocarcinomas STAT3 correlated with Cx43 (P=0.03, r=0.290) but not with Cx26. Thus, it appears that hormone dependent acceleration of cancer growth breaks the association between STAT3 and Cx expression. These associations become weaker as the tumors dedifferentiate from G1 to G3 endometrioid adenocarcinomas. The present study provides evidence that the loss of correlation between STAT3 and selected Cx proteins occurs in tumors with more aggressive behavior.

Entities:  

Keywords:  STAT3; connexin 32; connexin 43; endometrioid adenocarcinoma; estrogen and progesterone receptors

Year:  2016        PMID: 27313754      PMCID: PMC4888192          DOI: 10.3892/ol.2016.4550

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Eventual proapoptotic or anti-apoptotic impact of aberrantly expressed Cx43 and Cx26 can depend on ER-alpha overexpression in human endometrioid adenocarcinoma.

Authors:  Urszula Sulkowska; Andrzej Wincewicz; Luiza Kanczuga-Koda; Mariusz Koda; Stanislaw Sulkowski
Journal:  Gynecol Endocrinol       Date:  2015-08-21       Impact factor: 2.260

2.  Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line.

Authors:  Eriko Fujimoto; Hiromi Sato; Sumiko Shirai; Yoji Nagashima; Keiko Fukumoto; Hiromi Hagiwara; Etsuko Negishi; Koichi Ueno; Yasufumi Omori; Hiroshi Yamasaki; Kiyokazu Hagiwara; Tomohiro Yano
Journal:  Oncogene       Date:  2005-05-19       Impact factor: 9.867

3.  STAT3-dependent mouse embryonic stem cell differentiation into cardiomyocytes: analysis of molecular signaling and therapeutic efficacy of cardiomyocyte precommitted mES transplantation in a mouse model of myocardial infarction.

Authors:  Johnson Rajasingh; Evelyn Bord; Hiromichi Hamada; Erin Lambers; Gangjian Qin; Douglas W Losordo; Raj Kishore
Journal:  Circ Res       Date:  2007-09-06       Impact factor: 17.367

Review 4.  Mind the gap; regulation of gap junctional, intercellular communication by the SRC oncogene product and its effectors.

Authors:  Mulu Geletu; Aaron Trotman-Grant; Leda Raptis
Journal:  Anticancer Res       Date:  2012-10       Impact factor: 2.480

5.  Stat3 activity is required for gap junctional permeability in normal rat liver epithelial cells.

Authors:  Mulu Geletu; Chrystele Chaize; Rozanne Arulanandam; Adina Vultur; Claudia Kowolik; Aikaterini Anagnostopoulou; Richard Jove; Leda Raptis
Journal:  DNA Cell Biol       Date:  2009-07       Impact factor: 3.311

6.  Suppression of gap junctional intercellular communication via 5' CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells.

Authors:  Makoto Nishimura; Tsuyoshi Saito; Hiroshi Yamasaki; Ryuichi Kudo
Journal:  Carcinogenesis       Date:  2003-08-01       Impact factor: 4.944

7.  Overexpression of estrogen receptor-alpha gene suppresses gap junctional intercellular communication in endometrial carcinoma cells.

Authors:  Tsuyoshi Saito; Ryoichi Tanaka; Koya Wataba; Ryuichi Kudo; Hiroshi Yamasaki
Journal:  Oncogene       Date:  2004-02-05       Impact factor: 9.867

8.  Stat3 and gap junctions in normal and lung cancer cells.

Authors:  Stephanie Guy; Mulu Geletu; Rozanne Arulanandam; Leda Raptis
Journal:  Cancers (Basel)       Date:  2014-03-25       Impact factor: 6.639

9.  Correlations of differentially expressed gap junction connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with breast cancer progression and prognosis.

Authors:  Ivett Teleki; Attila Marcell Szasz; Mate Elod Maros; Balazs Gyorffy; Janina Kulka; Nora Meggyeshazi; Gergo Kiszner; Peter Balla; Aliz Samu; Tibor Krenacs
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

10.  Comparison of STAT3 with HIF-1alpha, Ob and ObR expressions in human endometrioid adenocarcinomas.

Authors:  Andrzej Wincewicz; Mariusz Koda; Mariola Sulkowska; Luiza Kanczuga-Koda; Stanislaw Sulkowski
Journal:  Tissue Cell       Date:  2008-06-25       Impact factor: 2.466

View more
  3 in total

Review 1.  PI3k and Stat3: Oncogenes that are Required for Gap Junctional, Intercellular Communication.

Authors:  Mulu Geletu; Zaid Taha; Patrick T Gunning; Leda Raptis
Journal:  Cancers (Basel)       Date:  2019-02-01       Impact factor: 6.639

2.  Hypoxia‑induced internalization of connexin 26 and connexin 43 in pulmonary epithelial cells is involved in the occurrence of non‑small cell lung cancer via the P53/MDM2 signaling pathway.

Authors:  Shang-Gan Zeng; Xiang Lin; Ji-Chun Liu; Jin Zhou
Journal:  Int J Oncol       Date:  2019-09-03       Impact factor: 5.650

3.  High GJB2 mRNA expression and its prognostic significance in lung adenocarcinoma: a study based on the TCGA database.

Authors:  Yun Tang; You-Jing Zhang; Zeng-Hong Wu
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.